Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.

PLoS One · 2020 · PMC7006931 · PMID 32032395

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

three months: 9.5 g/dl [7.3–12.5]), but there was a clear trend to reduce blood requirement (baseline: 7.5 [3.5–14] vs. 3 months: 2 [0–2]).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.